Printer Friendly

ENDOGEN, INC. ANNOUNCES SECOND QUARTER RESULTS

 BOSTON, Jan. 14 /PRNewswire/ -- Endogen, Inc. (OTC: ENDG) announced today that revenues for the second quarter ended Nov. 30, 1993 were $727,003, reflecting a 19% increase from revenues of $613,135 reported in the comparable period in 1992. Continued strong demand for the company's products, new product offerings, and intensive marketing efforts contributed to revenue growth. The net loss for the quarter was $(68,274), or (3 cents) per share compared to net income of $72,696, or 4 cents per share in the comparable period a year ago.
 Six month revenues were $1,511,103, up 27% from revenues of $1,189,737 reported in the comparable period in 1992. The net loss for the six months ended Nov. 30, 1993 was $(70,339), or (3 cents) per share compared to net income of $112,693, or 6 cents per share in the same fiscal period for the prior year.
 Since going public in March 1993, Endogen has accelerated expansion programs for product development and sales and marketing. The decrease in net income for the period is a reflection of increased expenditures in product development and marketing in advance of anticipated product revenues. "I am pleased with the revenue growth, which continued at a favorable rate," said Owen Dempsey, Endogen's president and CEO. "We are committed to our long-term strategy of pursuing revenue growth and consistent introduction of new and innovative products that respond to the needs of basic science researchers. We also look forward to the impact of Endogen's new 1994 Product Catalog of which 30,000 copies were mailed in December."
 Endogen, Inc. is a leading developer, manufacturer and supplier of advanced products for the biomedical research market. The company's products are used by scientists in search of treatments and cures to immunological diseases such as cancer and AIDS. Endogen markets three principal product lines worldwide, consisting of over 150 specialty reagents and 22 immuno-assay test kits.
 ENDOGEN, INC.
 Condensed Statement of Operations
 (Unaudited)
 Three Months Ended Six Months Ended
 11/30/93 11/30/92 11/30/93 11/30/92
 Revenue:
 Product sales $727,003 $613,135 $1,511,103 $1,189,737
 Costs & Operating
 Expenses:
 Cost of sales 228,575 152,701 463,045 355,968
 Selling & marketing 177,053 145,768 339,287 223,075
 General & admin. 232,880 126,313 464,818 266,610
 Research & develop. 165,193 112,458 334,410 225,503
 Total 803,701 537,240 1,601,560 1,071,156
 Income (loss) from
 operations (76,698) 75,895 (90,457) 118,581
 Interest income
 (expense), net 8,424 (3,199) 20,118 (5,888)
 Net income (loss) $(68,274) $72,696 $(70,339) $112,693
 Net income (loss)
 per share (3 cents) 4 cents (3 cents) 6 cents
 Weighted average
 shares outstanding 2,600,243 1,746,297 2,582,639 1,746,297
 Condensed Balance Sheet
 11/30/93 5/31/93
 (Unaudited)
 Assets
 Cash and cash equivalents $2,358,394 $2,583,738
 Accounts receivable, net 408,929 404,384
 Inventory and other
 current assets 652,986 542,920
 Property, plant and
 equipment, net 258,555 253,811
 Other assets 363,648 219,100
 Total $4,042,512 $4,003,953
 Liabilities and Stockholders' Equity
 Current liabilities $495,879 $566,299
 Long-term debt 233,634 82,501
 Stockholders' equity 3,312,999 3,355,153
 Total $4,042,512 $4,003,953
 -0- 1/14/94
 /CONTACT: Daniel A. Burns, investor relations manager of Endogen, 617-439-3250/
 (ENDG)


CO: Endogen, Inc. ST: Massachusetts IN: MTC SU: ERN

CM-DD -- NE011 -- 2164 01/14/94 16:34 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1994
Words:601
Previous Article:APPOINT TECHNOLOGIES ANNOUNCES PLAN TO DIVEST SUBSIDIARY; RELATED MANAGEMENT CHANGES
Next Article:MELAMINE CHEMICALS, INC. REPORTS SIX MONTHS RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters